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Abstract
Background: In Brazil, we are facing an alarming epidemic scenario of Yellow fever (YF), which is reaching the
most populous areas of the country in unvaccinated people. Vaccination is the only effective tool to prevent YF. In
special situations, such as patients with chronic immune-mediated inflammatory diseases (CIMID), undergoing
immunosuppressive therapy, as a higher risk of severe adverse events may occur, assessment of the risk-benefit
ratio of the yellow fever vaccine (YFV) should be performed on an individual level.
Main body of the abstract: Faced with the scarcity of specific orientation on YFV for this special group of patients, the
Brazilian Rheumatology Society (BRS) endorsed a project aiming the development of individualized YFV recommendations
for patients with CIMID, guided by questions addressed by both medical professionals and patients, followed an
internationally validated methodology (GIN-McMaster Guideline Development). Firstly, a systematic review was carried out
and an expert panel formed to take part of the decision process, comprising BRS clinical practitioners, as well as individuals
from the Brazilian Dermatology Society (BDS), Brazilian Inflammatory Bowel Diseases Study Group (GEDIIB), and specialists on
infectious diseases and vaccination (from Tropical Medicine, Infectious Diseases and Immunizations National Societies); in
addition, two representatives of patient groups were included as members of the panel. When the quality of the evidence
was low or there was a lack of evidence to determine the recommendations, the decisions were based on the expert
opinion panel and a Delphi approach was performed. A recommendation was accepted upon achieving ≥80% agreement
among the panel, including the patient representatives. As a result, eight recommendations were developed regarding the
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safety of YFV in patients with CIMID, considering the immunosuppression degree conferred by the treatment used. It was
not possible to establish recommendations on the effectiveness of YFV in these patients as there is no consistent evidence
to support these recommendations.
Conclusion: This paper approaches a real need, assessed by clinicians and patient care groups, to address specific questions
on the management of YFV in patients with CIMID living or traveling to YF endemic areas, involving specialists from many
areas together with patients, and might have global applicability, contributing to and supporting vaccination practices. We
recommended a shared decision-making approach on taking or not the YFV.
Background
Yellow fever: Disease and vaccine
Yellow fever (YF) is an infectious zoonotic disease caused
by an RNA arbovirus, belonging to the family Flaviviridae,
transmitted by hematophagous insects, especially of the
genera Aedes and Haemagogus. In Brazil, the main sylvatic
cycle of transmission involves mostly Haemagogus mosqui-
tos. The disease is both, endemic and epidemic, in tropical
regions of South America and Africa, and its clinical
spectrum is highly variable, ranging from asymptomatic to
severe disease, with a 50% mortality risk [1, 2].
In Brazil, although YF is endemic in the North and Cen-
tral West regions, it has become epidemic outside the
Legal Amazon in the last five years. The YF transmission
cycle occasionally re-emerges and, in the last decade, an
increase in viral circulation has been observed throughout
the country [3, 4]. From July 2016 to March 2017, 691
cases and 220 deaths were confirmed; an increase was no-
ticed during the same period of the following year, when
the records increased to 1127 cases and 328 deaths
(http://portalms.saude.gov.br/boletim-epidemiologico, ac-
cess December, 2018).
Vaccination is the only effective measure to prevent YF.
The rapid recognition of disease outbreaks in high-risk
areas, followed by the vaccination of 60 to 80% of the
population is crucial to prevent epidemics [5].
The YFV is composed of an attenuated live virus, specific
pathogen free (SPF) strain 17D or equivalent, cultivated in
chicken embryo eggs, and has been used for the prevention
of the disease since 1937. It is considered highly immuno-
genic, capable of immunizing 95 to 99% of adults and
approximately 90% of infants (< 2 years) one week after ap-
plication [3, 6, 7]. However, on the other hand, the YFV is
related to a potential risk of inducing an adverse event fol-
lowing vaccination (AEFV) [8].
According to the World Health Organization (WHO),
an AEFV is defined as any harmful medical occurrence
after vaccination, classified as local or systemic, even
without a clear causal relationship traced back to the
vaccine. In general, AEFVs are mild and transitory. They
generally occur three to seven days after vaccination and
usually last no longer than three to seven days. Local
manifestations (pain, erythema, and induration at the in-
jection site) or systemic manifestations, such as malaise,
tiredness, low fever, mild headache or myalgia may occur
[3, 6, 7].
The major concern regarding an AEFV is when it is
reported as a severe adverse event (SAE), characterized
by hospitalization required for at least 24 h, significant
dysfunction, and/or persistent secondary or congenital
abnormality and even death or risk of death [9].
Although rare, SAEs can occur, particularly post-primary
vaccination, mainly during immunization campaigns in
areas with no prior vaccine recommendation [10, 11].
SAEs related to the YFV are extremely rare and the risk
of dying from YF is considered higher than vaccination-
associated risks [5].
In Brazil, there are two vaccines available, derived from
the same strain, with very similar and comparable re-
sponse profiles and reactogenicity – YFV 17DD (Bioman-
guinhos©) and 17D-204 (Sanofi Pasteur©) [3, 6, 7, 12].
The current Brazilian immunization schedule recom-
mends a single subcutaneous 0.5ml dose at nine months
of age [6] and is contraindicated in some groups, as
follows [3, 5, 13]:
 infants younger than nine months for routine
immunization or younger than six months during
an epidemic;
 pregnant women or breastfeeding children under
six months of age, except during YF outbreaks,
when the risk of infection is high;
 severe allergies to egg protein;
 history of severe adverse reactions to previous doses;
 organ transplantation;
 previous history of thymus disease (myasthenia
gravis, thymoma, thymus absence or surgical
removal);
 severe immunodeficiency of any nature.
The most serious SAE related to YFV is associated
with viscerotropic disease (YEL-AVD), an acute
post-vaccination dysfunction that usually appears one to
four weeks after vaccination, with clinical manifestations
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ranging from a mild multisystem disease to multiple
organ failure and death. Virological and pathological
findings during necropsies of vaccinated patients showed
the replication and uncontrolled dissemination of the
17D or 17DD virus. The initial symptoms are nonspe-
cific, similar to YF manifestations. The most serious con-
dition associated with YEL-AVD is characterized by
hypotension, hemorrhage, and acute renal and respiratory
failure, with an overall case–fatality rate of approximately
50% [14, 15].
According to Staples et al. (2017), at least 100 cases of
YEL-AVD had been reported worldwide and none were
reported after revaccination until February 2017. In the
United States, the incidence of YEL-AVD is 0.25–0.4/
100,000 doses and in Brazil, 21 cases were reported from
2007 to 2012, at a rate of 0.04 cases per 100,000 adminis-
tered doses. In 2009, during the vaccination campaign in
the State of São Paulo, 0.31 cases per 100,000 doses applied
were observed, and in Rio Grande do Sul, the frequency
observed was 0.11 per 100,000 doses applied [16].
Another SAE is the yellow fever vaccine-associated neuro-
tropic disease (YEL-AND), which although not related to
death, can cause hypersensitive reactions, neurological mani-
festations (encephalitis, meningitis, Guillain-Barré syndrome,
etc.), and autoimmune diseases, involving the central and
peripheral nervous system [9, 17].
A single-dose vaccination has been implemented since
April 2017, however due to conflicting results on
immunity in long-term YFV studies it is still under
debate among vaccination experts [6, 18–21].
According to the WHO, the use of fractional-dose
YFV is a good strategy to avoid disease outbreaks as this
strategy rapidly increases vaccination coverage in areas
of risk [22]. Recently in Brazil, the Ministry of Health
started a campaign using YFV fractionated-dose due to
the current epidemic quickly spreading over the most
populous states.
Due to the current epidemiological setting, the vaccin-
ation against the YF virus will be extended and recom-
mended across the country. It is intended to be gradually
incorporated as part of the basic vaccination schedule in
all Brazilian States from July 2018 [4].
Yellow fever vaccine: Assessment of the immunogenicity
YFV is one of the most immunogenic vaccines. The highly
effective and long-lasting immunity caused by 17D makes
it an important research target for the development of
vaccines against related viruses and for understanding the
attenuation and immunological induction processes for
highly effective vaccines in general [23]. Studies have dem-
onstrated that humoral immunity is a primary protective
element in previously exposed individuals, and a single
vaccine may provide protection against global strains of
the YF virus [18, 23]. Approximately 90% of 17D-
immunized individuals are shown to be producing
neutralizing antibodies on the tenth day after vaccination,
and almost 100% are doing so by day 30 [21].
The post-immunization humoral responses to YFV
can be measured by the plaque reduction neutralization
test (PRNT). This is the gold standard correlation of
protection method, which is considered when more than
80% of virus neutralization at 1:10 dilution is detected in
the serum. The micro-PRTN90 has a sensitivity of 100%
and specificity of 94.7% for the yellow fever virus [24].
Other methods, such as the Indirect Immunofluorescence
Test (IFA), used to evaluate IgG antibodies, present false
positives with various viruses of the Flaviviridae family, and
although highly sensitive, it does not reach the specificity of
the PRNT. The specificity of these tests is impaired in
patients with Dengue fever history [25]. Thus, the neutraliz-
ing antibodies remain accepted as a correlate of protection
against the YF virus.
To date, there is no other adequate method to evaluate
the response to YFV in humans besides neutralizing anti-
bodies. Nevertheless, new alternatives based on the com-
plex modulation of innate immune cytokines induced by
YFV are being studied [26]. In addition, CD4+ and CD8+ T
cells strongly respond to 17D, with CD4+ T reaching their
highest level between seven and 14 days and CD8+ T be-
tween 14 and 30 days after vaccination. These cells slowly
decline over time, but remain detectable for more than 25
years, while another group of self-renewing and highly
responsive 17D-specific memory cells remains stable during
the same 25-year period. Complementary studies in
humans are required regarding cytokine and CD4+ and
CD8+ T cell counts in order to assess their real benefit as a
vaccine response marker [27].
Studies published to date (WHO, ACIP, and CDC)
have shown that approximately 88% of healthy individ-
uals remain seropositive for more than ten years after
the YFV [20]. On the other hand, Brazilian studies have
demonstrated a fall in protection after 5–10 years in
some groups [6, 24]. It is crucial to obtain further under-
standing about the YFV immunogenicity in patients with
CIMID, particularly in Brazil, since it is an endemic area
with frequent outbreaks of the disease.
Yellow fever vaccine in specific situations of
immunosuppression
In some situations, there is a higher risk of AEFV, and it
is important to evaluate the risk-benefit ratio on an indi-
vidual basis. In cases of moderate to severe acute febrile
illnesses, postponement of the vaccine is recommended
until resolution of the condition. Blood or organ donors
should wait for four weeks after vaccination before
donating; the immunosuppression degree of patients
with CIMID, undergoing immunosuppressive therapy,
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should be established in order to evaluate the safety of
receiving the YFV [3].
The CIMID concept is used to collectively describe a
group of heterogeneous diseases that share common in-
flammatory pathways and deregulation in the immune
system. These are responsible for chronic inflammation,
such as rheumatoid arthritis (RA), ankylosing spondylitis
(AS), psoriasis, psoriatic arthritis (PsoA), multiple scler-
osis (MS), systemic lupus erythematosus (SLE), and in-
flammatory bowel diseases (IBD), such as Crohn’s
disease and ulcerative colitis [28]. These diseases affect
approximately 5–8% of the population and cause signifi-
cant morbidity, mortality, and a high risk of infection [29].
The treatment of these diseases is based mainly on
immunosuppressive or immunomodulatory agents to
control chronic inflammation. The use of these medica-
tions, with different mechanisms of action, besides
changes in the immune system inherent in the under-
lying disease, lead to variable degrees of immunosup-
pression and, consequently, increase susceptibility to
infections, which is considered the major cause of mor-
bidity and mortality in this population [30]. As a result,
the immunogenicity of vaccines may be reduced. Fur-
thermore, the administration of live attenuated vaccines
(LAV) bears the potential risk of invasive infection with
the attenuated vaccine strain and should generally be
avoided in patients under immunosuppressive therapy;
this being the reason why these vaccines are generally
contraindicated in this population [31, 32].
According to the Brazilian Ministry of Health, the rec-
ommendation for YF vaccination is based on the routine
immunization of the population exposed to the virus,
residents or subjects travelling to endemic regions, in
the absence of contraindications. There are still some
controversial issues regarding contraindication, and they re-
quire caution, as well as the elderly population (over sixty
years old), and patients with different immunosuppression
degrees [3].
For patients with CIMID, it is essential to take into
account the risk of (rare) post-vaccination adverse events
and the protection provided by a highly effective vaccine
against a potentially lethal illness without specific treat-
ment. When evaluating the risk of severe AEFVs, we
should consider the underlying disease, its severity, level
of activity, and immunosuppression degree. At the same
time, we should consider the risk of contracting the YF
virus in areas of vaccine recommendation [15, 33, 34].
It is important to emphasize that none of the review arti-
cles or consensus formed by the panels of experts have
established specific recommendations or absolute contrain-
dications against the indication of LAV in patients with
CIMID, considering the particular differences between the
diseases and their treatment. Based on the knowledge that
the only effective measure to prevent YF is vaccination, and
that many immunocompromised patients have been inad-
vertently vaccinated without presenting an SAE [35], these
panels of specialists agree that there is no absolute contra-
indication for YFV in this setting and the risk and benefits
should be considered individually.
In this context, management should be individualized,
according to the underlying disease, medications used
and their doses, replication capacity of the attenuated
vaccine virus, and risk of infection. Risks related to LAV
potentially involve viral replication capability (elevated
with the YFV agent), availability of an antiviral agent
(such as acyclovir for varicella), immunoglobulins
(passive immunity), or an antimicrobial agent.
We conducted a systematic literature review on the
safety and effectiveness of the YFV in patients with
CIMID, guided by the most frequent questions addressed
by healthcare professionals and patients on this issue.
Thus, the objective of this study was to develop individu-
alized YFV recommendations for this special group of
patients.
Methods
This was an initiative of the Brazilian Rheumatology
Society (BRS); to develop YFV-specific recommenda-
tions for this special group of patients, considering the
national epidemiological scenario, based on scientific
evidence.
Study method
To develop the recommendations, the BRS followed an
internationally validated methodology, according to the
GIN-McMaster Guideline Development Checklist (https://
cebgrade.mcmaster.ca/guidelinechecklistonline.html). The
Society counted on a work group comprised of clinical
practitioners with expertise in different CIMID types, such
as the Brazilian Dermatology Society (BDS) and the Brazil-
ian Inflammatory Bowel Diseases Study Group (GEDIIB).
In addition, the BRS invited experts on infectious diseases
and vaccination (from Tropical Medicine, Infectious Dis-
eases and Immunization National Societies) to take part in
the process.
The chair of the group (GSP) was chosen and endorsed
by the BRS, who defined groups to run the process of de-
veloping recommendations: the oversight committee,
composed of five rheumatologists (LM, AMK, SK, MRA,
VMFT), specialists in systematic reviews and the Grading
of Recommendations Assessment, Development and
Evaluation Working Group (GRADE), and a postgraduate
student from the Evidence Based Medicine postgraduate
program (APR).
The oversight committee was responsible for defining
the questions that guided the recommendations via
weekly Skype meetings, keeping the guideline develop-
ment on track, the goals and objectives, timeline, task
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assignments, documenting the decisions, and proposing
the methodology for all steps. The committee was also
in charge of including and developing search strategies,
running searches and selection of evidence, and critically
appraising the existing evidence and establishing
methods for identifying additional evidence.
The other workgroup, the panel members, was composed
of experts representing the above-mentioned societies and
two representatives of National groups of patients (PT, ET).
These representatives are both very engaged in continuous
education and advocacy and have sufficient knowledge on
CIMID diseases, regularly giving on-line and presential sup-
port to patients around Latin America. They did not re-
ceive any incentive to participate in the panel and did not
receive any tool to help their decisions during the recom-
mendation development process. They participated in all
steps of the process, which were transparent to all mem-
bers, and their votes had the same weight as all others.
Search strategy
The systematic literature review was performed in elec-
tronic and manual databases, using terms derived from
the main question of the study, formulated using PICO
format (terms described in Table 1).
Analysis of the methodological quality of the studies
For this evaluation, the Cochrane Collaboration risk of
bias table was used for the intervention studies [36]. For
observational studies, we used the Newcastle-Ottawa
Quality Assessment Scale [37]. Studies that received
scores equal to or greater than six were considered to
have good methodological quality.
Quality of evidence
The quality of the evidence (QoE) reported in this sys-
tematic literature review was analyzed based on the
GRADE approach [38]. As studies with different levels
of evidence were included in the recommendation devel-
opment, the oversight committee chose to split them
into two categories: in comma-separated sequences or in
intervals, separated by hyphens [39].
Delphi methodology
When the quality of the evidence was low or there was a
lack of evidence, the opinion of the expert panel was
used to support the decisions to determining the
recommendations.
To achieve consensus among panel members, Delphi
methodology was employed [40]. A face-to-face meeting
was arranged and held on November 30, 2017 to present
the literature reviewed to the panel and train them on
Delphi methodology voting, where all participants
should anonymously assign a score from 0 to 100 on a
continuous scale to each recommendation, with 0 indi-
cating total disagreement and 100 absolute agreement.
Recommendations were refined and voted on by all
work groups (oversight and panel) through a series of
three online Delphi rounds supervised by the chair
(GSP). From these grades, a final level of agreement
(LoA) score was allocated to each recommendation. It
was a consensus for all work groups that a recommenda-
tion was accepted when it achieved ≥80% agreement
among the panel, including the patient representatives.
Sample
We included all the studies found by the search strategy
specified above, with no language restrictions.
Eligibility criteria
Studies included: clinical trials, observational studies,
and case studies on the effectiveness and/or safety of
YFV that included CIMID patients with or without
treatment.
Intervention
The YFV was considered as the intervention when
compared to placebo.
Outcomes
For assessing YFV safety, the following aspects were
considered:
 AEFV, most severe adverse events (SAE), including
YEL-AVD and YEL-AND,
Table 1 Terms used for the literature review search using the PICO Format
Population with or without
treatment
Patients with rheumatoid arthritis OR juvenile idiopathic arthritis OR systemic lupus erythematosus OR systemic
sclerosis OR psoriatic arthritis OR spondyloarthritis OR Sjögren’s syndrome OR vasculitis OR inflammatory myopathy
OR dermatomyositis OR psoriasis OR Crohn’s disease OR ulcerative colitis
Intervention yellow fever vaccine
Comparison Placebo OR no intervention
Outcomes immunization, safety, severe adverse events, viscerotropic disease associated with yellow fever vaccine, immunogenicity,
response, effectiveness, efficacy, seroconversion, disease activity: DAS28, ACR 30/50/70. BASDAI, SLEDAI, HAQ / CHAQ,
VASDAI, CMAS, MMT
Terms used for the search related to treatment: abatacept, acitretin, adalimumab, anti-CD20, anti-IL-1, anti-IL-6, anti-IL17, anti-IL23, anti-JAK, anti-TNF, azathioprine,
belimumab, canakinumab, certolizumab, cyclophosphamide, CTLA4 IgG, etanercept, golimumab, hydroxychloroquine, infliximab, leflunomide, methotrexate,
methylprednisolone, mycophenolate mofetil, prednisolone, prednisone, rituximab, secukinumab, sulfasalazine, tacrolimus, tocilizumab, tofacitinib, ustequikinumab
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 risk of infection with attenuated vaccine strain,
 relapse or worsening of underlying disease activity.
The response to YFV was evaluated considering the fol-
lowing terms as surrogates for efficacy: immunogenicity,
seroconversion, and effectiveness.
Questions defined using PICO format
Initial questions regarding YFV safety in patients with
CIMID, receiving or not immunosuppressive medications,
were divided according to vaccine exposure to primary
vaccination and revaccination (re-exposure) (see Table 2).
Study selection and data extraction
Two reviewers independently assessed the titles and ab-
stracts of all studies selected by the search strategy group.
The full texts of the eligible studies were then retrieved.
Two reviewers selected the studies to be included, and
disagreements were resolved either by consensus or by the
opinion of a third reviewer. A standard data extraction
sheet was developed for this review. For the eligible
studies, two reviewers extracted the data independently.
The discrepancies were resolved by discussion or, where
necessary, by consulting a third reviewer.
Results
Studies selected and data extracted
From the entire database search, 175 articles were identi-
fied, and nine additional studies were selected from other
sources (congress abstracts). Among the 184, only 36 were
eligible and 148 were excluded, either for not meeting the
inclusion criteria (113) or for being duplicates (35). After
evaluating the 36 selected studies, a further 19 were ex-
cluded for methodological reasons; they were not observa-
tional studies or randomized clinical trials. Finally, 17
studies were selected for qualitative analysis and none for
quantitative analysis. The flow chart in Fig. 1 depicts the se-
lection process for Systematic Reviews.
Eleven of the 17 selected studies were observational (co-
hort, case control, or cross-sectional studies) and 6 were
case series. Based on these 11 observational studies, a total
of 692 patients were included for the safety analyses. The
participants were subjects who had received the YFV des-
pite a diagnosis of CIMID and no SAE was reported.
There was no difference in AEFV occurrence between
patients and healthy individuals [35, 41–48].
Recently, Valim et al. (2017) carried out an observational
study evaluating the safety of selected patients with
rheumatic diseases after a primary YF vaccination. The
authors enrolled 241 patients with rheumatic diseases for
whom no SAE was reported and 40 healthy controls [46].
This is an ongoing study and we had access to only partial
results from a conference abstract.
All included studies had methodological limitations
regarding the design or development and did not describe
adequate statistical analysis data to evaluate the magnitude
of effect. In addition, we only had access to the partial re-
sults of three included studies at the time of our review, as
they were conference abstracts from ongoing studies [43,
46, 47]. For this reason, we could not estimate the effect or
quality of evidence.
Three studies [21, 42, 48] did not include randomly
selected controls and the vaccinated group was not homo-
geneous, with very different sample sizes in the control
group and intervention group. Only one study (Scheinberg
2010) included randomly selected controls and included a
homogeneous sample [44].
Scheinberg et al. (2010) carried out a study with 17
patients with RA who received a YFV booster during
treatment with methotrexate and infliximab. In 15 pa-
tients, serology was analyzed by immunofluorescence
before and after vaccination. The results were com-
pared with a control group. The YFV was adminis-
tered 30 days after the last infusion of anti-TNF. Of
17 patients, only one did not seroconvert. Although
there was a trend towards lower antibody titers in the
Table 2 Questions used to formulate the recommendations
1. Are there specific restrictions on the indication of YFV in patients with
CIMID baseline disease, activity, or medication use facing a yellow fever
outbreak?
2. Is the risk of SAE following primary or booster YFV vaccination higher
in patients with CIMID? Is this related to disease type or activity?
3. Is the risk of SAE following primary and booster YFV vaccination
higher in patients using corticosteroid or CsDMARD, TsDMARD or JAK
inhibitors?
4. Is the risk of SAE after primary or booster YFV vaccination higher in
patients with CIMID using immunosuppressive drugs (azathioprine,
cyclophosphamide, cyclosporine, mycophenolate mofetil/acid) or
bDMARD?
5. Should an interval be recommended between YFV application
(primary or booster) and initiation or restart of medications for CIMID
treatment?
6. Should a minimum interval be recommended between
discontinuation of medications for CIMID treatment and YFV application
(primary or booster)?
7. Does the concomitant application of other vaccines interfere in the
YFV response in patients receiving or not CIMID treatment?
8. Is there any contraindication of YFV in close contacts or people living
with CIMID patients?
9. Does the use of immunomodulatory and/or immunosuppressive
agents in patients with CIMID interfere in the YFV response or long-term
efficacy?
YFV: yellow fever vaccine; CIMID: chronic immune-mediated inflammatory
diseases; DMARD: disease modifying anti-rheumatic drugs; csDMARD
conventional synthetic DMARD – methotrexate, leflunomide, sulfasalazine and
antimalarials (hydroxychloroquine and chloroquine); tsDMARD: synthetic
target-specific DMARD – tofacitinib; bDMARD: biological DMARD – tumor
necrosis factor inhibitors/TNFi (adalimumab, certolizumab, etanercept,
golimumab, infliximab), T-lymphocyte costimulation modulator (abatacept),
anti-CD20 (rituximab), and IL-6 receptor blocker (tocilizumab)
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RA group, unfortunately, the authors did not apply
any statistical tests [44].
Five observational studies [41, 42, 44, 45, 48] evalu-
ated the neutralizing antibodies to YFV in 180 pa-
tients with CIMID using immunosuppressant drugs,
including corticosteroids, synthetic or biological. The
authors concluded that all immunocompromised
patients were able to develop a protective response to
the yellow fever booster. The quality of evidence was
very poor.
Oliveira et al. (2015) analyzed the presence of neutralizing
antibodies in 31 patients diagnosed with rheumatic diseases
who had been inadvertently vaccinated with a booster of
YFV (without the physician’s knowledge) [45] during a YF
outbreak (2007–2008). Twenty-three subjects with RA, five
with SLE, two with ES, and one with ankylosing spondylitis
were included in the study. The patients were taking vari-
ous immunomodulatory drugs, such as MTX, leflunomide,
infliximab, or rituximab. A plaque reduction neutralization
test (PRNT) was performed to evaluate the immunogen-
icity to the YFV, with values ≥794 mIU/ml considered pro-
tective. In total, 27 out of 31 (87%) presented protective
titers of neutralizing antibodies. The lowest PRNT value
was in a patient who had used rituximab prior to the
booster [45].
Another observational study collected data from pa-
tients using corticosteroids who were planning to travel to
endemic regions for YF. The control group consisted of
healthy individuals matched for age and history of YFV.
The safety and immunogenicity of the 17D vaccine was
evaluated. Forty participants in the study group and 77 in
the control group were enrolled. The main diseases of the
study group were RA and other CIMIDs. The dose of
prednisone or equivalent ranged from 5 to 20mg/day, and
71% had been using the drug for more than 15 days before
the YFV, with an average of ten months of use [48]. There
were no serious adverse events; however, the patient group
presented a higher frequency of mild reactions, with rela-
tive risk (RR) = 8.0 and a 95% confidence interval (CI):
1.4–45.9. In this study, the neutralizing antibodies were
also measured by PRNT. All participants had titers ≥1:10.
There were no differences between the groups that
received primary or booster YFV [48]. It is important to
mention they specifically evaluated patients vaccinated
while using corticosteroids. However, the dosage was low,
not reaching immunosuppressive doses. Furthermore, as
the study was not blind, bias may have occurred [48].
Recently, Wieten et al. (2016) studied 15 immuno-
compromised patients who were vaccinated inadvert-
ently or after a risk-benefit analysis had been
performed by the attending physician. Neutralizing
antibodies were measured by PRNT, and an analysis of
PBMC (peripheral blood mononuclear cells) and T
cells as well as analysis of the cytokine profile pro-
duced by CD8+ lymphocytes specific for the yellow
fever virus were performed. The results were compared
to a control group composed of 41 healthy individuals
who were matched for age, sex, and time of vaccin-
ation [41, 42].
The neutralizing antibody dosage was similar be-
tween groups, with 100% of the immunocompromised
individuals and 96.7% of the control group presenting
protective levels. Specific CD8+ cells, were also com-
parable in relation to the frequency, with a gradual
decline over the years after vaccination. Other results
showed that there were no significant differences in
the phenotypic and cytotoxic profile of specific T
cells. The production of cytokines was also equivalent
between the groups [41, 42].
This was the first study to analyze the profile of the
immunological alterations post the YFV in immunocom-
promised individuals, although the sample was small
and became even smaller when the authors performed
the analysis of subgroups.
In another study, Wieten et al. (2016) analyzed
blood samples from 15 immunocompromised patients
and 12 healthy controls in order to compare PRNT
and serology values by immunofluorescence. Of the
patients evaluated, 11 were on methotrexate, two on
etanercept, one on prednisone, and one on lefluno-
mide. The medication was withdrawn around two to
six weeks in three patients. Using the PRNT method,
100% of the study group demonstrated protective
levels of neutralizing antibodies compared to 83.3% of
Fig. 1 Flow chart of the studies selection process during the
systematic review
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the control group. Regarding immunofluorescence ser-
ology, only 47% of the study group was seropositive,
and no sample was positive in the control group.
There was no correlation between PRNT and im-
munofluorescence [21, 41, 42].
A recent Brazilian study by Ferreira et al. (2017), per-
formed a long-term follow-up including 144 RA patients
treated with immunomodulatory and immunosuppressive
specific drugs who were inadvertently vaccinated. The
authors evaluated the humoral and cellular immunity pro-
file to YFV and demonstrated a reduced frequency of
memory lymphocytes among previously vaccinated
patients when compared to healthy controls. Based on this
data, the authors concluded that patients taking synthetic
or biological drugs were unprotected by the 17DD YFV
after a five-year follow-up [43]. This is an ongoing study
and we had access to only partial results from a confer-
ence abstract.
There are some case reports in the literature to sup-
port these results, such as a 63-year-old woman diag-
nosed with Crohn’s disease who received the 17D
vaccine during the use of adalimumab. The vaccine was
given four days before the next dose, which is usually
administered every 14 days. Blood samples were col-
lected on days 12, 18, and 26 post-immunization for
viral RNA analysis and detection of neutralizing anti-
bodies. There were no adverse effects. No viremia was
detected on day 12, and from day 18 onward, protective
levels of neutralizing antibodies were recorded. In this
case, it is important to point out that it was the primary
dose [49].
All the studies were judged as very low quality of evi-
dence due to methodological limitations, including small
sample sizes and lack of statistical data to evaluate the
magnitude of the effect. Another limitation identified was
a wide range of follow-up and analyses applied in the
studies, varying from six days to eight years.
Additionally, given the lack of consensus on defining
immunosuppression degrees among national and inter-
national Societies and evidence to support this strategy,
the Brazilian societies involved in the treatment of pa-
tients with CIMID assembled to discuss and vote on it,
aiming to standardize these definitions and enable estab-
lishment of recommendations. A panel of 22 specialists,
representing several committees of the BRS, in addition to
two representatives of the Brazilian Society of Dermatology
(BDS), the Brazilian Infectious Diseases Society (BIDS), and
the study group on Inflammatory Bowel Diseases (GEDIIB),
conducted a careful literature review. This step was
followed by anonymous voting to categorize the immuno-
suppression degree of patients with CIMID. For this classi-
fication, more than 80% agreement was required among
the members for each item, applied to develop the recom-
mendations for vaccine indication or contraindication.
Complete information on this part of the guidelines process
will be published in a separate paper by the same work
group (Manuscript in preparation).
Table 3 summarizes the position of the BRS and the
immunosuppression degree conferred by the drugs used
to treat patients with CIMID, considering the class of
medication and mechanism of action.
As a result, eight recommendations were developed
regarding the safety of YFV in patients with CIMID and
the immunosuppression degree conferred by the treat-
ment used.
Since there was no consistent evidence to support any
kind of conclusion or position for the last question for-
mulated as part of the primary objective, on the im-
munogenicity to YFV in patients with CIMID, the
unanimous decision of the panel of members was that it
was not possible to establish recommendations on the
effectiveness, in the short and long-term, of YFV in
these patients; therefore, the results on this issue will
only be described.
Recommendations
1. YFV should not be administered to patients with
CIMID under high immunosuppression. For patients
with a low degree or no immunosuppression, it is
recommended that the risk of the vaccine be assessed
individually. This evaluation should be performed by
a physician, preferably the specialist assisting the
patient (QoE: very low, LoA: > 90% of agreement).
2. YFV should not be administered to patients with
CIMID with high activity of the underlying disease.
However, in clinically stable patients or those with
no activity of the underlying disease there is no
contraindication to vaccination. The risk to
vaccinate in these situations should be assessed
individually by a physician, preferably the specialist
assisting the patient (QoE: very low, LoA: > 90% of
agreement)
3. YFV should not be administered to patients with
CIMID using a high dose of corticosteroid. The risk
of vaccinating patients receiving low doses should be
assessed individually by a physician, preferably the
specialist assisting the patient (QoE: very low, LoA:
> 90% of agreement).
We emphasize an individual-based evaluation,
ideally shared decision making (SDM) [50], consider-
ing the risks and benefits of vaccination, especially in
a high-risk epidemiological setting, because of the
severity and mortality rate related to YF infection, as
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well as the possible adverse events of the YFV in an
immunosuppression context [8, 13].
The Center for Diseases Control and Prevention
(CDC) used the GRADE system to evaluate the evi-
dence of SAE following YFV and 1255 cases with a re-
port of SAE following YFV were identified. For the
majority (84%) of subjects, it was unknown if the SAE
occurred following a primary or booster dose of the
vaccine. Furthermore, it was not known how many of
the 437 million doses of YFV were administered as a
primary or booster dose. Of the 201 subjects for whom
SAE was reported, the dose type was known, whereas
14 (7%) occurred following a booster dose of vaccine
[13, 19, 51–55].
In this systematic review, YEL-AVD was reported for
72 subjects; in 41 (57%) it was unknown if the event
occurred following a primary or booster dose of the
vaccine. Of the 31 subjects for whom the dose type was
known, one (3%) subject had YEL-AVD after receiving
a booster dose of the vaccine; no laboratory testing was
performed for that case [10, 11, 14, 15, 34, 52, 56–60].
In the same review, YFV-AND was reported for 218
subjects. For 108 (50%) subjects it was not known
whether YEL-AVD occurred following a primary or
booster dose of the vaccine. Of the 110 subjects for
whom the dose type was known, three (3%) subjects re-
ported YFV-AND after receiving a booster dose of the
vaccine. All three cases were reported as an
autoimmune-mediated event rather than direct vaccine
viral invasion of the central nervous system and no
specific laboratory testing was available to assess
vaccine causality [10, 17, 52, 56–59, 61, 62].
SAE in altered immune status patients
It is well established that YFV is contraindicated in
people with a thymus disorder associated with abnor-
mal immune cell function, such as thymoma or myas-
thenia gravis. YFV is contraindicated in people with
AIDS or other clinical HIV manifestations, including
patients with CD4+ T lymphocyte values < 200/mm3
or < 15% of total lymphocytes for children aged < 6
years. This recommendation is based on the potential
increased risk of encephalitis in this population. It is
also contraindicated in patients with primary im-
munodeficiencies, as well as those with malignant
neoplasms or transplants.
There are no data regarding possible increased adverse
events or decreased vaccine effectiveness after YFV ad-
ministration to patients with other chronic medical con-
ditions (such as renal disease, hepatitis C virus infection,
diabetes mellitus, and CIMID). Factors to be considered
when assessing a patient’s general level of immune compe-
tence include disease severity and activity, complications,
comorbidities, and current treatment programs, mainly
immunosuppressants. As there are no specific data on the
use of YFV in these populations to date, the use of LAV is
contraindicated according to the majority of package
inserts in these therapies.
According to CDC, there are no data available on dis-
ease activity and medication used in nine patients diag-
nosed or potentially diagnosed with autoimmune
diseases who developed YEL-AVD by the year 2016 and
could potentially be under treatment with immunosup-
pressive agents. Four out of nine patients were older
than 60 years, and two had a previous history of thymec-
tomy – both situations are considered a risk factor for
YEL-AVD [11]. According to the CDC and Advisory
Committee on Immunization Practices (ACIP) recom-
mendations, there are no contraindications or precau-
tions for this special group of patients regarding
underlying diseases. However, the contraindications
should be carefully observed, and consideration given
to the precautions for vaccination when patients are
receiving immunosuppressive therapy, following the
recommendations for immunosuppressed individuals
[12, 13, 19].
Table 3 Immunosuppression degree conferred by drugs used
to treat patients with chronic immune-mediated inflammatory
diseases: Positioning of the Brazilian Societies of Rheumatology,
Dermatology and Study Groups on Inflammatory Bowel
Diseases
Non-immunosuppressed
Those clinically stable under the following conditions:
No drug treatment
Only using sulfasalazine or hydroxychloroquine or mesalazine or
acitretin
Using topical, inhaled, peri or intra-articular corticosteroids
Low immunosuppression degree
Using:
Methotrexate at a dose of ≤0.4 mg/kg/week or≤ 20 mg/week
Leflunomide at a dose of ≤20 mg/daya
Corticosteroid at a dose of ≤20 mg/day (or 2 mg/kg/day for patients
weighing < 10 kg) prednisone or equivalent
High immunosuppression degree
Using:
Corticosteroid at a dose of ≥20 mg/day (or > 2 mg/kg/day for patients
weighing < 10 kg) prednisone or equivalent, for a period ≥14 days
Pulsotherapy with methylprednisolone
Immunosuppressants as mycophenolate mofetil or sodic,
cyclosporine, cyclophosphamide, tacrolimus, azathioprine
JAK inhibitors, such as tofacitinibb
b-DMARD
bDMARD: biologic disease modifying anti-rheumatic drugs; As the dosage of
serum level of leflunomide is difficult and the studies on the risk of vaccinating
individuals taking leflunomide at the usual doses are lacked, in cases requiring
vaccination, a drug elimination regimen of 8 g of cholestyramine 3 times/day for
11 days or 50 g of activated charcoal 4 times/day for 11 days must be prescribed
(similar to Sanofi Pasteur Laboratory recommendation when a woman taking
leflunomide become pregnant). If the leflunomide plasma level determination is
available it is recommended to reach nondetectable levels (i.e., below 0.02mg/l)
before vaccination
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Nevertheless, there are some studies performed in
Brazil that have shown no SAE related to YFV. The
first, published by Mota et al. (2009), reported retro-
spective data from 70 patients with various rheumatic
diseases such as RA, SLE, Spo, and systemic sclerosis
(SyS) who were inadvertently vaccinated with YFV.
All participants were receiving immunosuppressive
therapy. Among them, 22.8% reported mild adverse
events such as rash, headache, and myalgia. There
were no serious adverse events, hospitalizations, or
deaths due to immunization [35].
Recently, Valim et al. (2017), enrolled 241 patients
with rheumatic diseases for whom no SAE was reported,
s described above [46]. Additionally, case reports of
patients with CIMID using synthetic or biological
DMARDs were described without any reported of SAE
[33, 35, 41, 42, 44, 45, 49, 63–67].
Since there are scarce data on LAV, such as YFV, in
patients with CIMID, guidelines on vaccination for this
group are less evidence-based than other immunosup-
pressive conditions. In addition, it is almost impossible
to establish a real causal correlation between an AEFV
related to YFV and a CIMID, as this group of diseases
encompasses a range of clinical presentation conditions
and multivariate manifestations, as well as they have par-
ticular differences considering the type of treatment, in
general inducing immunosuppressive drugs. These all
variables together inducing a wide variation in the
immunosuppression degree, which could be further
related to susceptibility to infections and can be consid-
ered a cause of SAE per se.
Therefore, this section provides recommendations based
on the best data available and the practices of experienced
clinicians. A special comment about the fractional YFV
dose campaign should be highlighted, as, besides the bal-
ance between risk/benefits, it is also necessary to consider
the shortage of the vaccine. In this situation, if there is an
endorsement by national health authorities, our advice is
to follow the same recommendations regarding the
vaccination safety in patients with CIMID.
4. Revaccination with YFV should not be administered
to patients with CIMID under high
immunosuppression. In specific situations in which a
booster is necessary, the risk of vaccinating patients
with a low or no immunosuppression degree should be
assessed individually by a physician, preferably the
specialist assisting the patient (QoE: Very low, LOA: >
90% of agreement)
Although booster doses of YFV are not recom-
mended in current epidemiological settings in Brazil,
this is a matter of debate. For ACIP and CDC, a
booster is recommended for special groups, such as
those with HIV, post-transplant patients, and may be
considered for travelers who received their previous
dose of YFV ≥10 years ago and plan to remain for a
prolonged period in endemic or ongoing outbreak
areas [13, 19].
5. In situations of risk, when YFV is indicated, a
minimum interval of four weeks is recommended
between application of the vaccine and the
initiation or resumption of treatment with
immunomodulatory and immunosuppressive drugs
(QoE: very low, LOA: > 90% of agreement).
6. In situations of risk, when YFV is indicated, a
minimum period after the suspension of medications
prior to the application of the vaccine is
recommended, varying according to the
immunosuppression degree. Advice on treatment
discontinuation should be individualized and given
by a specialist (QoE: very low, LOA: > 90% of
agreement).
There is no strong and consistent evidence to be used
as the foundation for establishing recommendations
about whether patients with CIMID should be undergo-
ing therapy or not when receiving LAV. The majority of
healthcare work in this field follows guidelines based on
the experience of other specialists, who manage im-
munosuppressive therapy in their clinical practice more
frequently (e.g. oncologists).
Papadopoulou and Sipsas (2014) performed a search for
all the guidelines available on the vaccination of adult
patients with CIMID. The authors identified specific
protocols in 21 national rheumatology societies, all of them
built on an expert opinion panel. Points of agreement
include avoiding the use of LAV in immunosuppressed pa-
tients. However, the most important differences were based
on the immunosuppression degree of patients under differ-
ent treatments, such as the steroid dose that induces im-
munosuppression, the time interval between LAV, and the
initiation of immunosuppressive treatment. The authors
concluded that these significant differences among national
recommendations on immunizations in patients with
CIMID reflected the lack of evidence-based data [32].
A defined safety period between the onset or with-
drawal from immunosuppressive therapy and a
vaccination with LAV in patients with CIMID has not
been studied; subsequently, the majority of the guide-
lines are based on expert opinion. There is consensus
between the guidelines among the international soci-
eties regarding the period recommended between
LAV and therapy onset, which is at least one month
[30, 31, 33, 68]. However, there is no consensus
among these experts on how long the temporary
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discontinuation of immunosuppressive medication
should be before vaccination with LAV.
Thus, considering the epidemiological scenario in
Brazil and the need for a specific recommendation on
YFV for this population, we were motivated to defend
our position that the immunosuppression degree
induced by the treatment should be the basis for an in-
dividualized and safer approach to the vaccination of
patients with CIMID. Complete information regarding
this study can be found in another publication from
this group (Manuscript in preparation). The recom-
mended period that clinicians should wait, after
discontinuation of therapy, to administer a live vaccine,
is shown in Table 4.
7. When YFV is indicated to patients with CIMID, it is
recommended that it not be applied concurrently with
another live attenuated virus vaccine, primarily with
MMR (measles, mumps, and rubella). When indicated,
a 28-day interval between the application of these
vaccines is recommended (QoE: Very low, LOA: > 90%
agreement)
There is no evidence that inactivated vaccines inter-
fere in the immune response to the yellow fever
vaccine. Therefore, inactivated vaccines can be admin-
istered either simultaneously or at any time before or
after the yellow fever vaccination. The ACIP recom-
mends that the YFV should be administered either simul-
taneously or 30 days apart from other live viral vaccines as
the immune response to one live virus vaccine might be
impaired if administered within 30 days of another LAV
[2, 69]. One study involving the simultaneous administra-
tion of YFV and MMR vaccines in children found a de-
crease in the immune response to yellow fever, mumps,
and rubella when the vaccines were given on the same day
versus 30 days apart. Additional studies are needed to
confirm these findings, but they suggest that, if possible,
the yellow fever and MMR vaccines should be adminis-
tered 30 days apart.
8. There is no contraindication of YFVin those inclose
contact with immunocompromised patients, since the
transmission of the vaccine virus without vector
participation is documented only through breast milk,
blood donation, and, possibly, by accidental contact
with biological materials (QoE: Very low, LOA: > 90%
of agreement)
Healthy and immunocompetent subjects living with
immunocompromised patients can and should receive
LAV as well as inactivated vaccines, such as MMR,
the rotavirus vaccine, varicella, and shingles. In
addition, these subjects can safely receive vaccines
recommended for travelers, such as typhoid fever and
yellow fever [70].
According to the CDC, there is no evidence that
people receiving YFV can eliminate the vaccine virus
through any specimens [19]. Although detected in the
urine of vaccinated individuals, the presence of the
yellow fever vaccine virus has never been related to this
route of transmission [71].
There is a theoretical risk of YFV being transmitted
through blood products, but patients should be allowed
to donate two to four weeks after vaccination [72, 73].
In April 2009, the transmission of the yellow fever
vaccine virus through breast milk was documented in
Brazil for the first time [73, 74].
Discussion
The development of tailored recommendations for indicat-
ing YFV to patients with CIMID, receiving immunosup-
pressive therapy or not, was a pragmatic project in the field
of rheumatology and related specialties. Given the paucity
of scientific literature on vaccination for this particular
group of patients, the most suitable approach to be adopted
was to gather specialists from different areas, together with
patients, in an attempt to define the recommendations in a
setting with a high YF burden, in light of the knowledge
that recommendations in the literature in different settings
may not be the most appropriate for this specific group.
Table 4 Minimal period recommended between therapy withdrawal and yellow fever vaccination in patients with CIMID
Drug Interval between withdrawal and YFV
Prednisone > 20mg/day or pulse methylprednisolone At least one month
Hydroxychloroquine, sulfasalazine, acitretin, methotrexate ≤20 mg/week, or leflunomide 20mg/daya Consider vaccination without interval
Methotrexate > 20 mg/week At least 1 month
Azathioprine, mycophenolate mofetil or sodic, cyclosporine, tacrolimus, or cyclophosphamide At least 3 months
Tofacitinib At least 2 weeks
Anti-cytokines and co-stimulation inhibitor 4–5 half-livesb
B-lymphocyte depletors 6–12 months
the medical criterion to carry out the drug elimination protocol before indicating the vaccine bbased on pharmacological half-life, except for
B-lymphocyte depletors
Pileggi et al. Advances in Rheumatology           (2019) 59:17 Page 11 of 15
Strengths
To our knowledge, this is the first paper to address
specific questions, using a Guidelines Grade approach,
involving specialists from many areas and patients, on
the management of YFV in patients with CIMID living
or traveling to YF endemic areas. This paper approaches
a real need, assessed by clinicians and patient care
groups and might have global applicability, contributing
to and supporting vaccination practices.
Additionally, the participation of patients is inedited in
the decision process as a motivation to shared
decision-making (SDM). It has been argued that SDM
represents the pinnacle of patient-centered care; well-in-
formed preference-based patient decisions might lead to
safer, more cost-effective healthcare, which in turn might
result in improved health outcomes. In practice, these
SDMs are seen to occur to a limited extent. In this
process, although a patient may not want to make any
final decision, they should still be involved in the devel-
opment of important but difficult recommendations,
such as eliciting their concerns and views. Knowledge
and awareness among both professionals and patients, as
well as tools and skills training, are needed for SDM to
become widely implemented [75].
Limitations
Due to the lack of evidence in the literature to help
the development of these recommendations, they
were mainly based on expert opinion and panel
making decisions. Further research and advances will
lead to future revisions and updates.
Thus, in particular here, we consider essential a SDM
approach on taking the YFV or not, since these recom-
mendations were based on few evidences and mostly in
expert opinion.
Conclusions
The number of patients with CIMID is increasing as well
as those exposed to therapy with a varied range of
immunosuppressive degrees. In Brazil, we are facing an
alarming epidemic scenario of YF, which is reaching the
most populous areas in the country in unvaccinated people.
The majority of vaccination guidelines for this special
population do not define recommendations or mea-
sures to plan the YFV for this particular group. Thus,
given the urgent need for specific recommendations on
YFV for this population and the lack of available
evidence in the literature, the Brazilian Society of
Rheumatology gathered a panel of experts, including
representatives from five other related Societies, to-
gether with patients, to build these recommendations,
prioritizing the vaccination safety and motivation for
SDM. These are summarized in Table 5.
Last but not least, our work group would like to
address a particular concern of great importance that
should be given to the vaccine effectiveness. Due to the
lack of evidence regarding short or long-term responses
to the primary vaccination, we were not able to draw
any recommendations or even advice in this field. How-
ever, we consider it fundamental to inform patients with
CIMID, who have been inadvertently vaccinated under
immunosuppression, that they may not have developed a
proper response to the vaccine, so they are advised to
take care when exposed to YF high-risk areas, until pro-
tection is confirmed by a post vaccination test (PRNT).
Finally, we hope this document will encourage all
health professionals involved in the care of this special
group of patients, to incorporate vaccination planning
into their clinical practice, considering both safety and
satisfactory immunogenicity.
Table 5 List of recommendations for yellow fever vaccine (YFV)
administration in patients with CIMID
1. YFV should not be administered to patients with CIMID under high
immunosuppression. For patients with a low degree or no
immunosuppression, it is recommended to assess individually the risk of
the vaccine. This evaluation should be performed by a physician,
preferably the specialist assisting the patient
2. YFV should not be administered to patients with CIMID with high
activity of the underlying disease. However, in clinically stable patients
or those with no activity of the underlying disease there is no
contraindication to vaccination. The risk to vaccinate in these situations
should be assessed individually by a physician, preferably the specialist
assisting the patient
3. YFV should not be administered to patients with CIMID using a high
dose of corticosteroid. The risk of vaccinating patients receiving low
doses should be assessed individually by a physician, preferably the
specialist assisting the patient
4. Revaccination with YFV is not recommended for patients with CIMID
under high immunosuppression. In specific situations in which a booster
is necessary, the risk of vaccinating patients with a low or no
immunosuppression degree should be assessed individually by a
physician, preferably the specialist assisting the patient
5. In situations of risk, when YFV is indicated, a minimum interval of four
weeks is recommended between application of the vaccine and the
initiation or resumption of treatment with immunomodulatory and
immunosuppressive drugs
6. In situations of risk, when YFV is indicated, a minimum period after
the suspension of medications prior to the application of the vaccine is
recommended, varying according to the immunosuppression degree.
Advice on treatment discontinuation should be individualized and given
by a specialist
7. When YFV is indicated in patients with CIMID, it is recommended that
it not be applied concurrently with another live attenuated virus
vaccine, primarily with the MMR (measles, mumps, and rubella). When
indicated, a 28-day interval between the application of these vaccines is
recommended
8. There is no contraindication of YFV in those in close contact with
immunocompromised patients, since the transmission of the vaccine
virus without vector participation is documented only through breast
milk, blood donation, and, possibly, by accidental contact with
biological materials
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